CELG
Celgene

Conference date: April 24, 2014 @ 6:00 AM Pacific Time

Celgene in 2017: $375 per share or more [January 14, 2013]
Celgene Up Over 100% in a Year. Still a Buy? [July 30, 2013 at Seeking Alpha]
Celgene Sees Revenue Doubling by 2017 [January 26, 2013]
Celgene Up on Psoriatic Arthritis Data [September 6, 2012]

Analyst Conference summaries and reports available:

2014
Celgence (CELG) analyst conference call Q4 2013
Celgence (CELG) analyst conference call Q1 2014
 
 
01/30/2014
4/24/2014
 
Q4 2013
Q1 2013
Q2 2013
Q3 2013
2013
Celgence (CELG) analyst conference call Q4 2012
Celgence (CELG) analyst conference call Q1 2013
Celgence (CELG) analyst conference call Q2 2013
Celgence (CELG) analyst conference call Q3 2013
01/24/2013
04/25/2013 
07/25/2013
10/24/2013 
Q4 2012
Q1 2013
Q2 2013
Q3 2013
2012
Celgence (CELG) analyst conference call Q4 2011
Celgence (CELG) analyst conference call Q1 2012
Celgence (CELG) analyst conference call Q2 2012
Celgence (CELG) analyst conference call Q3 2012
01/26/2012
4/26/2012
07/26/2012 
10/25/2012
Q4 2011
Q1 2012
Q2 2012
Q3 2012
2011
Celgence (CELG) analyst conference call Q4 2010
Celgence (CELG) analyst conference call Q1 2011
Celgence (CELG) analyst conference call Q2 2011
Celgence (CELG) analyst conference call Q3 2011
01/27/2011
 04/28/2011
07/28/2011 
 10/27/2011
Q4 2010
Q1 2011  
 Q2 2011
Q3 2011
2010
Celgence (CELG) analyst conference summary Q4 2009
Celgence (CELG) analyst conference summary Q1 2010
Celgence (CELG) analyst conference summary Q2 2010
Celgence (CELG) analyst conference call Q3 2010
01/28/2010
04/29/2010 
 07/29/2010
 10/28/2010
Q4 2009
 Q1 2010
Q2 2010  
Q3 2010  
2009
Celgene analyst conference summary q4 2008
Celgence (CELG) analyst conference summary Q1 2009
Celgence (CELG) analyst conference summary Q2 2009
Celgence (CELG) analyst conference summary Q3 2009
01/29/2009
04/30/2009
 07/23/2009
10/22/2009 
Q4 2008
Q1 2009
 Q2 2009
 Q3 2009
2008
Celgene Analyst Conference Summary Q3 2008
Celgene analyst conference summary Q2 2008
Celgene q1 analyst conference summary 2008
Celgene analyst conference summary for Q 2007
10/23/2008
07/24/2008
05/08/2008
01/31/2008
Q3 2008
Q2 2008
Q1 2008
Q4 2007
2007
Celgene analyst conference summary Q3 2007
CELG Q2 2007
celg summary

10/25/2007
07/26/2007
05/03/2007

 02/01/2007
Q3 2007
Q2 2007
Q1 2007

 Q4 2006

Celgene is a biotechnology company; products include Thalomid, Revlimid, Abraxane and Pomalyst.

Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Celgene Withdraws Revlimid Extension in Europe [June 21, 2012 Celgene press release]
Celgene Short and Long Views [April 27, 2012]
Celgene Q3 shows model strength [Nobember 7, 2011]
Celgene Readies Arsenal [August 2, 2011]
Celgene (CELG) ASH Data Points [December 11, 2010]
Celgene Gathers Momentum [November 1, 2010]
Celgene Q1 Advance on Revlimid, Vidaza [May 5, 2010]
Celgene Q4 2009 Earnings and Revenue Estimates [January 11, 2010]
Celgene to Grow Rapidly [September 7, 2008]
Celgene Data for Revlimid, Vidaza, Amrubicin [June 15, 2008]
Celgene Optimism [February 4, 2008]
Celgene (CELG) and Pharmion (PHRM) [November 24, 2007 blog]
Pharmion Acquisition [November 19, 2007 press release]
Celgene in Hypergrowth [May 23, 2007 blog]

I own this stock

Celgene Web site:

main page
investor page

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but its possible. Before making or terminating an investment you should always verify any factual basis of your decision.